Trimethylamine-containing compounds for diagnosis and prediction of disease
AssigneeThe Cleveland Clinic Foundation
InventorsStanley L. Hazen, Zeneng Wang, Bruce S. Levison
Life of this patent
Estimating the term…
Abstract
The present invention provides markers and methods for determining whether a subject, particularly a human subject, has or is at risk of developing, a disease such as cardiovascular disease, diabetes mellitus, insulin resistance, metabolic syndrome, NAFLD (Nonalcoholic Fatty Liver Disease) or NASH (Nonalcoholic Steatohepatitis) (e.g., within the ensuing year, two years, and/or three years). The present application also relates to the use of such markers and methods for monitoring the status of such diseases in a subject or the effects of therapeutic agents on subjects with such diseases.
Claims4
A method of detecting crotonobetaine in a plasma or serum sample, comprising:
- a) obtaining a biological sample, wherein said biological sample is from a human subject with cardiovascular disease, and wherein said biological sample is a plasma sample, a serum sample, or a urine sample;
- and
- b) treating said biological sample under conditions such that the concentration of crotonobetaine present in said biological sample is determined by mass spectrometry.
Dependencies are inferred from the claim text.